Trying a different primary endpoint did not help Entresto in heart failure with preserved ejection fraction, but Novartis seemingly still sees a path forward.
Bristol-Myers Squibb’s byzantine Checkmate-227 study yields one flop and one technical success that, in reality, counts for nothing.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Hopes for lumateperone rest on schizophrenia as bipolar data raise questions.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…